Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
| ▸ | IRAK2 | O43187 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264224 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23763239 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21105720 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23860570 | 1.00 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21070419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL31664231 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21107419 | 0.93 | IRAK4 (0.86) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945382 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23945438 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL22906395 | 0.92 | IRAK4 (0.84) | IRAK4IRAK2CLK1CLK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4132524-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | Aclaris Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210338669-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021195562-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | MAPKAPK2, MAP3K2, MAPK9 | IRAK4 220/4885IRAK2 90/4885CLK1 165/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK2 33/4885CLK1 889/4885 |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK2 33/4885CLK1 889/4885 |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK2 33/4885CLK1 889/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20210338669-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885IRAK2 33/4885CLK1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.